Health ProductsDear Healthcare Professional Letter

Archived – Important Drug Safety Information on VIOXX® – Merck Frosst Canada Inc.

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Issue: Important Safety Information
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Introduction

This is duplicated text of a letter from Merck Frosst Canada Ltd.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Details

[Text of letter begins]

Important Drug Safety Information

April 15, 2002

Dear Health Care Professional,

Merck Frosst Canada, in consultation with Health Canada, would like to bring to your attention changes which are being made to the product monograph for VIOXX® (rofecoxib) which include cardiovascular safety information. VIOXX® is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits the cyclooxygenase-2 (COX-2) enzyme and is indicated for the acute and chronic treatment of the signs and symptoms of osteoarthritis, relief of pain in adults and treatment of primary dysmenorrhea.

The information below should be taken into consideration and caution should be exercised when VIOXX® is used in patients with a medical history of ischemic heart disease.

The VIGOR (VIOXX® Gastrointestinal Outcomes Research) study was designed to evaluate the comparative gastrointestinal (GI) safety of VIOXX® 50 mg once daily [twice the highest dose recommended for chronic use in osteoarthritis (OA)] versus naproxen 500 mg twice daily (common therapeutic dose) in patients with rheumatoid arthritis (an unapproved indication in Canada). Patients were not permitted to use concomitant acetylsalicylic acid (ASA) or other antiplatelet drugs. In the 8076 patients (mean age 58; VIOXX® n=4047, naproxen n=4029) with a median duration of exposure of 9 months, the risk of developing a serious cardiovascular thrombotic event was significantly higher in patients treated with VIOXX® 50 mg once daily (n=45) as compared to patients treated with naproxen 500 mg twice daily (n=19). In VIGOR, mortality due to cardiovascular thrombotic events (7 vs 6, VIOXX® vs naproxen, respectively) was similar between the treatment groups.

In a placebo-controlled trials database derived from 2 studies with a total of 2142 elderly patients (mean age 75; VIOXX® n=1067, placebo n=1075) with a median duration of exposure of approximately 14 months, the number of patients with serious cardiovascular thrombotic events was 21 vs 35 for patients treated with VIOXX® 25 mg once daily versus placebo, respectively. In these same 2 placebo-controlled studies, mortality due to cardiovascular thrombotic events was 8 versus 3 for VIOXX® versus placebo, respectively.

The significance of the cardiovascular findings from these 3 studies (VIGOR and 2 placebo-controlled studies) is unknown. Prospective studies specifically designed to compare the incidence of serious cardiovascular (CV) events in patients taking VIOXX® versus NSAID comparators or placebo have not been performed.

Because of its lack of platelet effects, VIOXX® is not a substitute for ASA for cardiovascular prophylaxis. Therefore, in patients taking VIOXX®, antiplatelet therapies should not be discontinued and should be considered in patients with an indication for cardiovascular prophylaxis. As noted in the current Product Monograph for VIOXX®, concomitant administration of low-dose ASA with VIOXX® may result in an increased rate of GI ulceration or other complications, compared to the use of VIOXX® alone. Prospective, long-term studies on concomitant administration of VIOXX® and ASA evaluating cardiovascular outcomes have not been conducted.

In the VIGOR study, the incidence of hypertension adverse experiences on VIOXX® 50 mg (twice the highest dose recommended for chronic use in osteoarthritis) was 8.5% compared to 4.0% on naproxen 500 mg twice daily (common therapeutic dose). Clinical trials with VIOXX® at daily doses of 12.5 and 25 mg in patients with osteoarthritis have shown effects on hypertension similar to those observed with comparator NSAIDs; these occurred with an increased frequency with chronic use of VIOXX® at daily doses of 50 mg.

In patients with fluid retention, hypertension, or heart failure, VIOXX® should be used with caution and introduced at the lowest recommended dose.

As noted above, the VIGOR study was designed to evaluate the comparative GI safety of VIOXX®. Although the risk of GI toxicity is not completely eliminated with VIOXX®, the results of the VIGOR study demonstrated that in patients treated with VIOXX®, the risk of GI toxicity with VIOXX® 50 mg once daily is significantly less than with naproxen 500 mg twice daily.

The following standard Contraindications set by Health Canada for all NSAIDs will be added to the Product Monograph for VIOXX®:

  • Active peptic ulcer, active GI bleeding, or active inflammatory disease of the bowel
  • Significant hepatic impairment or active liver disease
  • Severe renal impairment (creatinine clearance less than 0.5 mL/sec: 30 mL/min) or deteriorating renal disease (individuals with lesser degrees of renal impairment are at a risk of deterioration of their renal function when prescribed NSAIDs and must be monitored)

The identification, characterization, and management of drug-related adverse events are dependent on the active participation of health care professionals in adverse drug reaction reporting programmes. Any occurrences of congestive heart failure, hypertension, thromboembolism, or other serious and/or unexpected adverse events in patients receiving VIOXX® should be reported to:

Merck Frosst Canada Ltd.
P.O. Box 1005,
Pointe-Claire-Dorval,
Québec,
H9R 4P8

Attention: Director, Medical Services

Your professional commitment in this regard has an important role in protecting the well-being of your patients by contributing to early signal detection and informed drug use.

Patient safety is of paramount importance to Merck Frosst Canada. We routinely review data from completed studies and clinical use of our products.

Should you have any questions or require additional information concerning the use of VIOXX®, please contact Merck Frosst Canada Ltd. at 1-800-567-2594 from 8:30 am to 5:30 pm, Eastern Standard Time, Monday to Friday.

Sincerely,

original signed by

Jacques Courville, M.D.
Vice President, Medical Research

®Registered Trademark of Merck & Co., Inc. Used under license.

Any suspected adverse reactions can also be reported to:

Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0201C2
OTTAWA, Ontario, K1A 1B9
Tel: (613) 957-0337 or Fax: (613) 957-0335
Toll free for consumers and health professionals:
Tel: 866 234-2345, Fax: 866 678-6789
cadrmp@hc-sc.gc.ca

The ADR Reporting Form can be found in The Canadian Compendium of Pharmaceuticals and Specialties, or on the TPD website, along with the ADR Guidelines.

[Text of letter ends]

 

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime